CTIM-24. PHASE II TRIAL OF RHIL-7-HYFC IN PATIENTS WITH HIGH-GRADE GLIOMA DEMONSTRATED ACCEPTABLE SAFETY PROFILE AND REDUCED LYMPHOPENIA

Authors: Yuping Derek Li, Jingqin Rosy Luo, Cierra Grote, Leslie Nehring, Ruth Katumba, Kelsey Etter, Kaiden Barozinsky, Sara Ferrando-Martinez, Kristina Stermer, Byung Ha Lee, Tanner Johanns, Omar Butt, Jiayi Huang, Jian L Campian, Milan G Chheda

Published: 2024-11-11

DOI: 10.1093/neuonc/noae165.0357

Source: Full article


Abstract

Abstract